

**WHAT IS CLAIMED IS:**

1. An isolated NMA SP polypeptide, which is a polypeptide of *Neisseria meningitidis*,  
5 and has a molecular weight of about 40 kD to about 55 kD as determined in SDS  
polyacrylamide gel electrophoresis.
2. The NMA SP polypeptide of claim 1, which has a molecular weight of about 44 TO  
53 kD.
- 10 3. The NMA SP polypeptide of claim 1, wherein the *Neisseria meningitidis* is selected  
from the group consisting of Types A-L and W.
4. The NMA SP polypeptide of claim 3, which *Neisseria meningitidis* is Type A, Type  
15 B, Type C or Type W.
5. The NMA SP polypeptide of claim 1, comprising a sequence selected from the group  
consisting of SEQ ID NOs: 2, 11, or 12, a sequence substantially homologous thereto, and a  
fragment thereof.
- 20 6. The NMA SP polypeptide of claim 1 or a peptide fragment thereof, which  
specifically binds an antibody that specifically binds to a protein having the sequence  
selected from the group consisting of SEQ ID NOs: 2, 11, or 12,.
- 25 7. A peptide fragment of the NMA SP polypeptide of claim 1.
8. A peptide fragment of the NMA SP polypeptide of claim 5.
9. A peptide fragment of the NMA SP polypeptide of claim 6.
- 30 10. An isolated antibody that specifically binds the NMA SP polypeptide of claim 1 or a  
fragment thereof.
11. An isolated antibody that specifically binds the NMA SP polypeptide of claim 5 or a  
35 fragment thereof.

12. An isolated antibody that specifically binds the NMA SP polypeptide of claim 6 or a fragment thereof.
13. The isolated antibody of claim 10, 11, or 12 which is a cytotoxic antibody that mediates complement killing of *Neisseria meningitidis*
14. An antigenic composition comprising the NMA SP polypeptide of any of claims 1, 5, or 6 and a pharmaceutically acceptable carrier or diluent.
15. An antigenic composition comprising the peptide fragment of claim 7, 8, or 9 and a pharmaceutically acceptable carrier or diluent.
16. The antigenic composition of claim 14 additionally comprising one or more adjuvants or immunostimulatory compounds.
17. The antigenic composition of claim 15 additionally comprising one or more adjuvants or immunostimulatory compounds.
18. The antigenic composition of claim 16 further comprising one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
19. The antigenic composition of claim 18, wherein the lipid is a phospholipid.
20. The antigenic composition of claim 17 further comprising optionally one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
21. The antigenic composition of claim 20, wherein the lipid is a phospholipid.
22. A vaccine composition comprising the NMA SP polypeptide of any of claims 1, 5, or 6 and a pharmaceutically acceptable carrier or diluent.
23. A vaccine composition comprising the peptide fragment of claim 7, 8, or 9 and a pharmaceutically acceptable carrier or diluent.

24. The vaccine of claim 22 additionally comprising one or more adjuvants or immunostimulatory compounds.
25. The vaccine of claim 23 additionally comprising one or more adjuvants or immunostimulatory compounds.
26. The vaccine of claim 24 further comprising one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
27. The vaccine of claim 26, wherein the lipid is a phospholipid.
28. The vaccine of claim 25 further comprising one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
29. The vaccine of claim 28, wherein the lipid is a phospholipid.
30. A pharmaceutical composition comprising the NMA SP polypeptide of any of claims 1, 5 or 6 and a pharmaceutically acceptable carrier or diluent.
31. A pharmaceutical composition comprising the peptide fragment of claim 7, 8, or 9 and a pharmaceutically acceptable carrier or diluent.
32. The pharmaceutical composition of claim 30 additionally comprising one or more adjuvants or immunostimulatory compounds.
33. The pharmaceutical composition of claim 31 additionally comprising one or more adjuvants or immunostimulatory compounds.
34. The pharmaceutical composition of claim 32 further comprising optionally one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
35. The pharmaceutical composition of claim 34, wherein the lipid is a phospholipid.

36. The pharmaceutical composition of claim 33 further comprising optionally one or more immunogens selected from the group consisting of lipids, lipooligosaccharides, proteins, attenuated organisms and inactivated whole cells.
- 5 37. The pharmaceutical composition of claim 36, wherein the lipid is a phospholipid.
38. A pharmaceutical composition comprising the antibodies of claim 10, 11, 12 or 13.
39. An isolated DNA comprising a nucleotide sequence encoding the NMA SP  
10 polypeptide of claim 1, 5 or 6 or fragment thereof.
40. An isolated DNA comprising a nucleotide sequence encoding the peptide of SEQ ID NOs: 2, 11 or 12, or fragment thereof.
- 15 41. An isolated DNA having the sequence of SEQ ID NOs: 1, 10 or 13, or fragment thereof.
42. An isolated DNA having the sequence of SEQ ID NOs: 3, 4, 8, 9, 14-15, 17-20, or the complement thereof.
- 20 43. An isolated DNA encoding an NMA SP polypeptide, which comprises a nucleotide sequence that hybridizes under high stringency conditions to the sequence of SEQ ID NOs: 1, 10 or 13 or the complement thereof.
- 25 44. An isolated DNA which comprises a nucleotide sequence that hybridizes under high stringency conditions to the sequence of SEQ ID NOs: 1, 3, 4, 8, 9, 10, 13-15, 17-20, or the complement thereof.
45. A pharmaceutical composition comprising the isolated DNA of any one of claims  
30 39, 40, 41, 42, 43 or 44.
46. A method of producing an immune response in an animal comprising immunizing the animal with an effective amount of the NMA SP polypeptide of any of claims 1, 5 or 6.
- 35 47. A method of producing an immune response in an animal comprising immunizing the animal with an effective amount of the peptide fragment of claim 7, 8, or 9.

48. Plasmid pNmAH116 obtainable from *E. coli* Top10 (pNmAH116), as deposited with the ATCC and assigned accession number 98839.

49. A method for assaying for an agent that interacts with NMA SP polypeptide comprising:

- a. contacting a cell expressing NMA SP polypeptide with an agent labeled with a detectable marker for a time sufficient to allow the agent to interact with the polypeptide;
- b. washing the cells; and
- c. detecting any marker associated with the cells,

10 in which any cell associated marker indicates that the agent interacts with the NMA SP polypeptide and wherein any agent that interacts with NMA SP indicates that the agent is useful as a diagnostic, prophylactic or therapeutic agent against *Neisseria meningitidis* infection.

15 50. An antagonist which inhibits the activity or expression of the NMA SP polypeptide of claim 5.

51. A method for identifying compounds which interact with and inhibit or activate an activity of the NMA SP polypeptide of claim 5 comprising:

- 20 contacting a composition comprising the polypeptide with the compound to be screened under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in the presence or absence of a signal generated from the interaction of the compound with the polypeptide.

25

30

35